CNO Financial Group, Inc. (CNO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal a positive outlook with strong revenue growth across multiple product lines, improved expense ratio guidance, and strategic capital deployment. Despite some unclear management responses, the strong D2C sales and partnerships, along with optimistic guidance, outweigh the concerns. The company's focus on shareholder returns through share repurchases and investments in growth is likely to drive a positive stock price movement. Given the market cap of $2.98 billion, a positive reaction of 2% to 8% is anticipated over the next two weeks.
Key Financial Performance
Total new annualized premiums $125 million, up 26% year-over-year. Reasons for the increase include double-digit insurance sales growth in both divisions.
Operating earnings per diluted share $1.29, up 16% year-over-year. This growth was driven by favorable insurance product margin and solid investment results, reflecting growth in the business and expansion of the portfolio book yield.
Book value per diluted share (excluding AOCI) $38.10, up 6% year-over-year. No specific reasons for the change were mentioned.
Life and Health NAP Up 27% year-over-year. Reasons include steady execution and dedication to serving the middle-income market.
Total life insurance Up 33% year-over-year. Reasons include process and technology enhancements, diversification of direct marketing channels, and increased direct marketing spend by third-party partners.
Direct-to-consumer life insurance sales Up 56% year-over-year. Reasons include process and technology enhancements, diversification of direct marketing channels, and increased direct marketing spend by third-party partners.
Total Health NAP Up 21% year-over-year. Reasons include strong customer demand for solutions to protect against out-of-pocket gaps in medical coverage and the growing cost of healthcare.
Supplemental Health Up 23% year-over-year. No specific reasons for the change were mentioned.
Long-term care Up 7% year-over-year. No specific reasons for the change were mentioned.
Medicare Supplement Up 33% year-over-year. Reasons include a growing shift in consumer preferences from Medicare Advantage to Medicare Supplement.
Medicare Advantage policies sold Down 24% year-over-year. Reasons include a growing shift in consumer preferences from Medicare Advantage to Medicare Supplement.
Annuity collected premiums Up 2% year-over-year, totaling nearly $475 million. Reasons include sustained growth and long-term relationships established by agents.
In-force account values Up 8% year-over-year, exceeding $13 billion for the first time. No specific reasons for the change were mentioned.
Client assets in brokerage and advisory Up 28% year-over-year, surpassing $5 billion. Reasons include sustained growth and strategic initiatives.
Producing agent count Up 11% year-over-year. Reasons include investments in training and sales tools.
Worksite Life and Health NAP Up 20% year-over-year. Reasons include geographic expansion initiatives and investments in training and sales tools.
Life insurance sales (Worksite) Up 24% year-over-year. No specific reasons for the change were mentioned.
Hospital Indemnity insurance Up 53% year-over-year. No specific reasons for the change were mentioned.
Critical Illness insurance Up 17% year-over-year. No specific reasons for the change were mentioned.
Accident insurance Up 15% year-over-year. No specific reasons for the change were mentioned.
Net investment income allocated to products Up 7% year-over-year. Reasons include an increase in yield and growth in the business.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Annualized Premiums: Record total new annualized premiums of $125 million, up 26%.
Direct-to-Consumer Life Insurance: Record sales up 56%, driven by process and technology enhancements, diversification of marketing channels, and increased marketing spend by third-party partners.
Medicare Supplement: Sales up 33%, reflecting a shift in consumer preferences from Medicare Advantage to Medicare Supplement.
Annuity Collected Premiums: Up 2%, totaling nearly $475 million, marking the ninth consecutive quarter of growth.
Geographic Expansion in Worksite Division: Contributed 42% of NAP growth in the quarter, marking the seventh consecutive quarter of growth from this program.
Operational Efficiency in Simplified Life Products: Accelerated underwriting delivered an 89% instant decision rate on submitted policies, up 11%.
Exit from Worksite Fee Services Business: Decision to exit fee services business to focus on core insurance business, expected to improve operating return on equity starting in Q4 2025.
Bermuda Reinsurance Treaty: Ceded approximately $1.8 billion of Supplemental Health U.S. statutory reserves to Bermuda affiliate, expected to improve operating ROE through 2027.
Shift in Medicare Product Strategy: Focus on Medicare Supplement due to consumer preference shift and reduced benefits in Medicare Advantage plans.
Streamlining Worksite Operations: Exiting fee services business to sharpen focus on core insurance products and align resources to growth areas.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Exit from Worksite Fee Services Business: The company decided to exit the fee services business due to its underperformance, contributing a pretax annual loss of approximately $20 million. This decision was driven by intensified competition, lower-cost alternatives, and new technologies disrupting the market position. The exit process is expected to incur charges of $15 million to $20 million and will be completed by the first half of 2026.
Medicare Advantage to Medicare Supplement Shift: There is a growing shift in consumer preferences from Medicare Advantage to Medicare Supplement plans, reversing a decade-long trend. This shift is attributed to leading Medicare Advantage sponsors paring back plans and benefits, which could impact fee income from the distribution of Medicare Advantage products.
Impairment of Goodwill and Intangibles: The company recorded a $96.7 million impairment in nonoperating income related to the goodwill and intangibles of Web Benefit Design and DirectPath acquisitions. This reflects updated financial projections and an increasingly competitive market for the fee services business.
Higher Claims in Medicare Supplement: Unfavorable morbidity within Medicare Supplement products was noted, which could impact margins and profitability in this segment.
Underperformance in Worksite Fee Services Business: The Worksite fee services business underperformed expectations, contributing to modestly unfavorable income results in the quarter.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Operating ROE Improvement: CNO expects to accelerate operating ROE improvement through 2027 by an additional 50 basis points due to the execution of a second Bermuda treaty and changes to the Worksite Division's fee services business.
Direct-to-Consumer (D2C) Life Insurance Sales: D2C life insurance sales were up 56% in Q3 2025, benefiting from process and technology enhancements, diversification of marketing channels, and increased direct marketing spend by third-party partners. However, this level of spending is not expected to repeat in Q4 2025.
Medicare Product Trends: A shift in consumer preferences from Medicare Advantage to Medicare Supplement plans is expected to continue, driven by leading MA sponsors paring back plans and benefits. This trend presents an opportunity to expand the total number of households served.
Worksite Fee Services Business Exit: CNO plans to exit the Worksite fee services business by the first half of 2026, which is expected to improve operating return on equity starting in Q4 2025, with full effects emerging by year-end 2026.
2027 Operating ROE Target: CNO revised its operating ROE target for 2027 to an improvement of 200 basis points, up from the prior target of 150 basis points, versus a run rate of approximately 10% in 2024.
2025 Operating Earnings Per Share Guidance: CNO narrowed its operating EPS range to $3.75 to $3.85, reflecting adjustments in expense ratio, effective tax rate, and fee income projections.
Excess Cash Flow Guidance: CNO raised its guidance for excess cash flow to the holding company to a range of $365 million to $385 million, up from $200 million to $250 million, incorporating the impact of the new Bermuda reinsurance transaction.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends returned to shareholders: $76 million in the quarter and $310 million year-to-date.
Share repurchases: $60 million of excess capital deployed on share repurchases in the quarter, contributing to an 8% reduction in weighted average diluted shares outstanding.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the strong D2C sales and the impact of new partnerships?
A:CEO Gary Bhojwani mentioned that the company is selective about partnerships, citing an example of targeting the Hispanic market through partnerships. Growth is expected to continue, though Q4 may not be as strong due to Q3 advertising expense pull-forwards. CFO Paul McDonough did not provide specific guidance but echoed the positive growth outlook.
Q:Does the $20 million annual earnings loss from the services business flow through the fee income line?
A:CFO Paul McDonough confirmed that the $20 million annual earnings loss is part of the fee income segment and that segment should improve by about $20 million annually.
Q:What is the total addressable market for health life and long-term care liabilities available to Bermuda?
A:CFO Paul McDonough did not provide specific quantitative details but mentioned exploring opportunities to cede additional business, particularly life reserves, to Bermuda for diversification. He emphasized the Bermuda platform's role in serving middle-income consumers in underserved markets.
Q:Will the direct expense ratio fall after DirectPath and Web Benefits Design wrap up in 2026?
A:CFO Paul McDonough stated that the $20 million annualized impact includes all expenses, and the expectation is that the direct expense ratio will improve after exiting the business.
Q:Are there ongoing earnings benefits or statutory impacts from the assumption review?
A:CFO Paul McDonough noted a $2 million quarterly benefit on a GAAP basis for Supplemental Health, while Chief Actuary Jeremy Williams confirmed no statutory impacts.
Q:How much of the Worksite insurance business is linked to the platforms being shut down, and is the $20 million GAAP loss equivalent to the cash impact?
A:CEO Gary Bhojwani stated there would be minimal impact on Worksite insurance sales as the business has grown without the fee business. CFO Paul McDonough indicated that the $20 million GAAP loss is a reasonable proxy for cash flow.
Q:What are the forward cash benefits from the Supplemental Health business and the fee services exit?
A:Chief Actuary Jeremy Williams mentioned a reduction in strain and additional cash flows for Supplemental Health. CFO Paul McDonough confirmed that the $20 million freed up from the fee services business would also have a cash impact.
Q:How will the additional cash flow from the Bermuda transaction be used?
A:CFO Paul McDonough stated that while there will be elevated cash at the holding company, the focus will be on measured share repurchases and investments in sales growth and a tech modernization project. Share repurchase levels will likely align with Q3 2025 levels.
Q:What is the cadence of the revised ROE target and its drivers?
A:CFO Paul McDonough explained that the 12% ROE target includes a 50 basis point improvement in 2025, with further benefits from the fee services exit and Bermuda treaty emerging in 2026-2027. CEO Gary Bhojwani emphasized the need for continuous improvement beyond the 12% target.
Q:What are the claims trends and assumption review impacts for the Medicare Supplement business?
A:Chief Actuary Jeremy Williams confirmed a 10% average rate increase in filings, consistent with trends incorporated in the annual actuarial assumption update.
Q:Why is the producing agent count flat despite strong NAP growth, and will this impact future growth?
A:CEO Gary Bhojwani acknowledged tougher comps but expects growth to continue, supported by a softening employment market and agent recruitment efforts. He emphasized prioritizing productivity over agent count.
Q:Does the exit from certain businesses change the approach to inorganic growth?
A:CEO Gary Bhojwani acknowledged lessons learned from the exits and emphasized the need for better handling of acquisitions. He noted successful minority stakes in other ventures but stated that the experience would impact future inorganic growth strategies.
Q:What is the cadence for reinsuring in-force business to Bermuda?
A:CFO Paul McDonough stated that one deal per year is a reasonable expectation, with a balance to be maintained in ceding reserves to Bermuda.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantitative details for the total addressable market for health life and long-term care liabilities available to Bermuda and the exact forward cash benefits from the Supplemental Health business. Additionally, they did not provide precise numbers for the impact of assumption updates on cash flows or the cadence of reinsuring in-force business to Bermuda.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advantage product
Agent
DC result
Design DirectPath
Life Health
ROE improvement
Supplemental Health
Worksite Division
Worksite fee
Worksite insurance
acquisition Web
capital holdco
dedication
digit
effect
enhancement
exit charge
expense ratio
fee income
fee service
holdco liquidity
impact
impairment
improvement basis
income result
insurance Worksite
loss
process
product result
projection
reinsurance
reserve
result Worksite
result record
sale DC
sale Worksite
sale division
surrender
transaction
CNO Transcript
CNO Financial Group, Inc. (CNO) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call indicates strong financial performance with significant growth in key insurance segments, robust ROE, and disciplined capital management. The Q&A reveals management's confidence in sustaining growth and improving ROE, despite some market uncertainties. The company's strategic focus on demographic trends and business growth supports a positive outlook. However, the lack of precise guidance on future ROE improvements and mortality trends adds some uncertainty. Given the company's market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
CNO Financial Group, Inc. (CNO) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call reflects a positive outlook with strong financial performance, improved ROE targets, and increased shareholder returns. Despite some challenges in discretionary purchases and Medicare Advantage, the company expects growth in Medicare Supplement sales, aligning with demographic trends. The Q&A session revealed confidence in hitting targets and maintaining regulatory relationships, although there were some vague responses. The market cap suggests moderate sensitivity to positive news, leading to an expected stock price increase of 2% to 8% over the next two weeks.
CNO Financial Group, Inc. (CNO) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary and Q&A reveal a positive outlook with strong revenue growth across multiple product lines, improved expense ratio guidance, and strategic capital deployment. Despite some unclear management responses, the strong D2C sales and partnerships, along with optimistic guidance, outweigh the concerns. The company's focus on shareholder returns through share repurchases and investments in growth is likely to drive a positive stock price movement. Given the market cap of $2.98 billion, a positive reaction of 2% to 8% is anticipated over the next two weeks.
CNO Financial Group, Inc. (CNO) Q2 2025 Earnings Call Transcript
Positive7-29
The earnings call summary and Q&A indicate strong financial performance, with growth across divisions, solid investment income, and a positive outlook on direct-to-consumer sales. While there were no specific new partnership announcements, the reaffirmation of 2025 guidance and stable financial health are positives. The Q&A addressed potential concerns, showing confidence in sustaining growth and managing competition. The market cap suggests moderate sensitivity, leading to a positive short-term stock price reaction.
CNO Slides
CNO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
